QuANTUM-First: Efficacy by age in newly diagnosed FLT3-ITD–positive AML
Presented by Dr Pau Montesinos (Hospital Universitario y Politècnico La Fe, Valencia, Spain)
Dr Pau Montesinos, a haematologist at the Hospital Universitario y Politècnico La Fe in Valencia, Spain, presented a post hoc analysis of the phase 3 QuANTUM-First study. This analysis evaluated the impact of age (<60 years vs. ≥60 years) on the efficacy of quizartinib in patients with newly diagnosed FLT3-ITD-positive AML. The efficacy subgroup analysis by age was consistent with the primary analysis, demonstrating the benefit provided by quizartinib. Notably, the benefit was more pronounced in patients younger than 60 years.
References:
Montesinos P, EHA2024 #P589
With the educational support of:
